Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Greene

Showing results (351-360 of 410) with videos related to

Pageof 41
Sort By:
Circulation|November 13, 2020
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular DiseaseJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 2, 2016
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysisLesley A Inker, Hasi Mondal, Tom Greene, et al.
Hypertension (Dallas, Tex. : 1979)|November 23, 2012
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney diseaseMahboob Rahman, Tom Greene, Robert A Phillips, et al.
Annals of Internal Medicine|February 26, 2019
Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical TrialRajnish Mehrotra, Daniel Cukor, Mark Unruh, et al.
Journal of the American Society of Nephrology : JASN|March 19, 2011
Use of aspirin associates with longer primary patency of hemodialysis graftsBradley S Dixon, Gerald J Beck, Laura M Dember, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 1, 2012
Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKDFrancis B Gabbai, Mahboob Rahman, Bo Hu, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Hypertension (Dallas, Tex. : 1979)|December 15, 2022
Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention TrialCatherine G Derington, Adam P Bress, Andrew E Moran, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 2, 2019
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAndrew S Levey, Ron T Gansevoort, Josef Coresh, et al.
Pageof 41

Showing results (351-360 of 410) with videos related to

Sort By:
Pageof 41
Circulation|November 13, 2020
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular DiseaseJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 2, 2016
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysisLesley A Inker, Hasi Mondal, Tom Greene, et al.
Hypertension (Dallas, Tex. : 1979)|November 23, 2012
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney diseaseMahboob Rahman, Tom Greene, Robert A Phillips, et al.
Annals of Internal Medicine|February 26, 2019
Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical TrialRajnish Mehrotra, Daniel Cukor, Mark Unruh, et al.
Journal of the American Society of Nephrology : JASN|March 19, 2011
Use of aspirin associates with longer primary patency of hemodialysis graftsBradley S Dixon, Gerald J Beck, Laura M Dember, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 1, 2012
Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKDFrancis B Gabbai, Mahboob Rahman, Bo Hu, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Hypertension (Dallas, Tex. : 1979)|December 15, 2022
Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention TrialCatherine G Derington, Adam P Bress, Andrew E Moran, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 2, 2019
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAndrew S Levey, Ron T Gansevoort, Josef Coresh, et al.
Pageof 41